Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1561 to 1575 of 1977 results for nice guidelines

  1. Rheumatoid arthritis in adults: management (CG79)

    This guidance has been updated and replaced by NICE guideline NG100.

    Withdrawn guideline

  2. Neuropathic pain in adults: pharmacological management in non-specialist settings (CG96)

    This guidance has been updated and replaced by NICE guideline CG173.

    Withdrawn guideline

  3. Eating disorders in over 8s: management (CG9)

    This guidance has been updated and replaced by NICE guideline NG69.

    Withdrawn guideline

  4. Coeliac disease: recognition and assessment (CG86)

    This guidance has been updated and replaced by NICE guideline NG20.

    Withdrawn guideline

  5. Type 2 diabetes: The management of type 2 diabetes (CG87)

    This guidance has been updated and replaced by NICE guideline NG28.

    Withdrawn guideline

  6. Low back pain in adults: early management (CG88)

    This guidance has been updated and replaced by NICE guideline NG59.

    Withdrawn guideline

  7. Substance misuse interventions for vulnerable under 25s (PH4)

    This guidance has been updated and replaced by NICE guideline NG64.

    Withdrawn guideline

  8. Community engagement (PH9)

    This guidance has been updated and replaced by NICE guideline NG44.

    Withdrawn guideline

  9. HIV testing: increasing uptake in black Africans (PH33)

    This guidance has been updated and replaced by NICE guideline NG60.

    Withdrawn guideline

  10. Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)

    Evidence-based recommendations on lusutrombopag (Mulpleo) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure.

    Technology appraisal guidance
    Published
    8 January 2020
    View recommendations

    Sections for TA617

  11. Improving outcomes in colorectal cancer (CSG5)

    This guidance has been updated and replaced by NICE guideline NG151.

    Withdrawn guideline

  12. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (TA98)

    This guidance has been updated and replaced by NICE guideline NG87.

    Withdrawn guidance

  13. Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure (TA48)

    This guidance has been updated and replaced by NICE guideline NG107 

    Withdrawn guidance

  14. Febuxostat for the management of hyperuricaemia in people with gout (TA164)

    This guidance has been updated and replaced by NICE guideline NG219.

    Withdrawn guidance

  15. The clinical effectiveness and cost effectiveness of anakinra for rheumatoid arthritis (TA72)

    This appraisal has been updated and replaced by NICE guideline CG79. 

    Withdrawn guidance